India, Oct. 25 -- Roche Holding AG (RHHBY) announced positive pivotal results from its Phase III Krascendo 1 study, showing that investigational therapy divarasib significantly outperformed currently approved KRAS G12C inhibitors in patients with previously treated KRAS G12C-mutated non-small cell lung cancer (NSCLC).
The study met its primary and key secondary endpoints, with divarasib demonstrating statistically significant and clinically meaningful improvements in both overall survival (OS) and progression-free survival (PFS) compared with first-generation KRAS G12C inhibitors sotorasib and adagrasib.
Patients treated with divarasib experienced a 44% reduction in the risk of death, while median overall survival reached approximately 18...